Search results for "blas"

showing 10 items of 2217 documents

Surgical Treatment of Extravasation Injuries

2005

The authors present their experience of treating anti-cancer drug extravasation by means of a composite surgical technique that consists of infiltration with physiological solution and hyaluronidase and subsequent manual aspiration of solutes alternated with profuse irrigation of the infiltrated area. In the immediate post-op we carry out a medical therapy that consists of calciparine and topic antibiotic and/or steroid creams. Since the year 2000 this technique has been used on 25 patients. We have had neither complications nor scars. Copyright 2005 Wiley-Liss, Inc Surgical treatment of extravasation injuries. Napoli P, Corradino B, Badalamenti G, Tripoli M, Vieni S, Furfaro MF, Cordova A,…

AdultMalemedicine.medical_specialtyantiblastictreatment KeyWords Plus:ANTITUMOR AGENTSextravasation injury; antiblastic; prevention; treatmentANTITUMOR AGENTS; APPROPRIATE MANAGEMENT; TISSUE EXTRAVASATION; HYALURONIDASE [Author Keywords]Drug ExtravasationTherapeutic irrigationScarsAntineoplastic AgentsTISSUE EXTRAVASATIONAPPROPRIATE MANAGEMENTCicatrixpreventionBiopsymedicineHumansCalciparineAuthor Keywords:extravasation injurySurgical treatmentTherapeutic IrrigationAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryBiopsy NeedleGeneral MedicineHYALURONIDASEMiddle Agedmedicine.diseaseHandExtravasationSurgeryAnti-Bacterial Agentsanticancer drugsTreatment OutcomeOncologyAnesthesiaSurgeryFemalemedicine.symptombusinessInfiltration (medical)Extravasation of Diagnostic and Therapeutic Materials
researchProduct

Clinical experience and perinatal outcome of blastocyst transfer after coculture of human embryos with human endometrial epithelial cells: a 5-year f…

2003

Abstract Objective To evaluate the reproductive and neonatal outcome of blastocyst transfer after coculture with human endometrial epithelial cells in IVF and oocyte donation. Design Retrospective study. Setting Private assisted reproductive center. Patient(s) Two hundred sixty women undergoing IVF and 469 oocyte recipients. Intervention(s) IVF or intracytoplasmic sperm injection (ICSI) and transfer of at least one blastocyst after coculture with human endometrial epithelial cells. Main outcome measure(s) Blastocyst formation rate, implantation and pregnancy rates, neonatal outcome, and congenital birth defects. Results Among patients who had transfer with their own oocytes, 1,193 of 2,349 …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentBiologyEndometriumIntracytoplasmic sperm injectionCongenital AbnormalitiesEndometriumPregnancyRisk FactorsmedicineHumansBlastocystEmbryo ImplantationSex Ratioreproductive and urinary physiologyRetrospective StudiesGynecologyPregnancyurogenital systemBlastocyst TransferPregnancy OutcomeObstetrics and GynecologyEmbryo cultureEpithelial Cellsmedicine.diseaseEmbryo TransferEmbryo MammalianEmbryo transferCoculture Techniquesmedicine.anatomical_structureReproductive Medicineembryonic structuresGestationFemalePregnancy MultipleFollow-Up StudiesFertility and sterility
researchProduct

Etoposide Treatment in Recurrent Medulloblastoma

1994

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosine arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60+ months. Etoposide seems to be an active agent in medulloblastoma.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentNeutropeniaGastroenterologyRecurrencePrednisoneInternal medicinemedicineHumansSpinal Cord NeoplasmsNeoplasm MetastasisChildEtoposideEtoposideMedulloblastomaChemotherapyBrain Neoplasmsbusiness.industryGeneral MedicineRecurrent MedulloblastomaPrognosismedicine.diseaseFrontal LobeSurgeryTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthToxicityFemaleMethotrexateNeurology (clinical)Tomography X-Ray ComputedbusinessMedulloblastomamedicine.drugNeuropediatrics
researchProduct

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a mu…

1995

Summary Purpose Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the headneck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods Eighty patients with recurrent and/ or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%).…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansNeoplasm MetastasisAgedChemotherapybusiness.industryVinorelbineHematologyMiddle Agedmedicine.diseaseSurgeryRegimenOncologyEpidermoid carcinomaTolerabilityFluorouracilHead and Neck NeoplasmsCarcinoma Squamous CellFemaleFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation

1996

von Hippel-Lindau (VHL) disease is a pleiotropic disorder featuring a variety of malignant and benign tumors of the eye, central nervous system, kidney, and adrenal gland. Recently the VHL gene has been identified in the chromosomal region 3p25-26. Prognosis and successful management of VHL patients and their descendants depend on unambiguous diagnosis. Due to recurrent hemangioblastomas, a29-year-old patient without familial history of VHL disease was diagnosed to be at risk for the disease. Histopathological examination of a small renal mass identified a clear cell tumor with a G1 grading. Genetic characterization of the germline and of the renal tumor was performed. Polymerase chain reac…

AdultMalemedicine.medical_specialtyvon Hippel-Lindau DiseaseTumor suppressor geneDNA Mutational AnalysisMolecular Sequence Dataurologic and male genital diseasesPolymerase Chain ReactionGermlineGermline mutationVon Hippel–Lindau tumor suppressorGeneticsmedicineHumansGenes Tumor SuppressorSpinal Cord NeoplasmsVon Hippel–Lindau diseaseGerm-Line MutationPolymorphism Single-Stranded ConformationalGenetics (clinical)Sequence Deletionbiologymedicine.diagnostic_testHomozygoteCytogeneticsExonsmedicine.diseaseKidney Neoplasmsfemale genital diseases and pregnancy complicationsHemangioblastomaPedigreeKaryotypingChromosomal regionbiology.proteinCancer researchFemaleChromosomes Human Pair 3Chromosome DeletionFluorescence in situ hybridizationHuman Genetics
researchProduct

Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I

1998

Plasmas of patients with Tangier disease (TD) lack lipid-rich α-HDL which, in normal plasma, constitutes the majority of high density lipoprotein (HDL). Residual amounts of apolipoprotein (apo)A-I in TD plasma occur as lipid-poor or even lipid-free preβ-HDL. By contrast to normal plasma, TD plasma does not convert preβ-HDL into α-HDL. Moreover, fibroblasts of TD patients were found to be defective in secreting cholesterol or phospholipids in the presence of lipid-free apoA-I. We have therefore hypothesized that both defective conversion of preβ-HDL into α-HDL and defective lipid efflux from TD cells onto lipid-free apoA-I result from a disturbance in phospholipid transfer occurring in both …

AdultMaletransferring phospholipidsPhospholipidTangier diseasePhosphatidic AcidsQD415-436PhosphatidylinositolsBiochemistrychemistry.chemical_compoundEndocrinologyTangier diseasePhosphatidylcholinePhospholipid transfer proteinExtracellularmedicineHumansCells CulturedPhosphatidylethanolamineApolipoprotein A-ICholesterolPhosphatidylethanolaminesReverse cholesterol transportnutritional and metabolic diseasesBiological TransportCell BiologyFibroblastsmedicine.diseaseMolecular biologyfamilial HDL deficiencyreverse cholesterol transportLipoproteins LDLphospholipid transfer proteinsprebeta-HDLTangier disease; transferring phospholipidschemistryPhosphatidylcholinesFemalelipids (amino acids peptides and proteins)cholesterol efflux
researchProduct

Repair of the mandibular nerve by means of autologous nerve grafting after resection of the lower jaw

1973

Summary On the basis of two cases we demonstrate our method of autologous nerve grafting for substitution of the mandibular nerve after mandibular resection. The sural nerve served as a donor nerve, the graft was imbedded microsurgically at the juncture points by means of a perineurial interfascicular nerve suture. Oversized grafts of about 20 cm in length were chosen intentionally in order to insert them without tension between the stumps of the recipient nerve and outside the regeneration zone of the bone. In both cases complete resensibilization of the lower lip was reached after about six months.

AdultMicrosurgerymedicine.medical_specialtyMandibular NerveMandibular nerveLower lipSural nerveTransplantation AutologousResectionAmeloblastomaPostoperative ComplicationsSural Nervestomatognathic systemmedicineHumansParesthesiaChildNerve graftingbusiness.industryGeneral MedicineAnatomyDenervationMandibular resectionLipNerve RegenerationOsteotomySurgeryMandibular Neoplasmssurgical procedures operativeFemaleSurgeryEpineurial repairNerve suturebusinessJournal of Maxillofacial Surgery
researchProduct

Oral versus intravenous vinorelbine: clinical safety profile

2005

The availability of chemotherapeutic drugs administrable by oral route represents a step forward in the management of cancer patients. Among oral agents, vinorelbine is particularly interesting for its pharmacological characteristics and clinical efficacy. Oral vinorelbine is rapidly absorbed (1.5-3 hours) with an elimination half-life of approximately 40 hours. It shows a low level of binding to plasma proteins (13%), is highly bound to platelets (78%) and has a hepatic metabolism and an absolute bioavailability of 40% with a moderate and similar interpatient variability for the two forms. Food has no influence on the pharmacokinetic profile of oral vinorelbine even if nausea/vomiting is l…

AdultNauseaAdministration OralBiological AvailabilityPharmacologyVinblastineVinorelbineAbsorptionEatingTherapeutic indexCytochrome P-450 Enzyme SystemPharmacokineticsOral administrationNeoplasmsmedicineHumansPharmacology (medical)Infusions IntravenousAgedbreast cancer non-small cell lung cancer (NSCLC) oral vinorelbinebusiness.industryStandard treatmentAge FactorsVinorelbineGeneral MedicineMiddle AgedAntineoplastic Agents PhytogenicLiverVomitingmedicine.symptombusinessDrug metabolismHalf-Lifemedicine.drug
researchProduct

Investigating the Antioxidant and Cytocompatibility of Mimusops elengi Linn Extract over Human Gingival Fibroblast Cells

2021

Background—chlorhexidine (CHX) is most commonly used as a chemical plaque control agent. Nevertheless, its adverse effects, including teeth discoloration, taste alteration and calculus build-up, limit its use and divert us to medicinal herbs. The purpose of the study was to evaluate the phytochemical composition, antioxidant potential, and cytotoxic effects of Mimusops elengi Linn extract (ME) over normal human cultured adult gingival fibroblasts (HGFs). Methods—in vitro phytochemical screening, total flavonoid content, antioxidant potential by DPPH and Nitric Oxide (NO) radical scavenging activity, and cytotoxic effects of ME extracts over HGF were explored. The viability of HGF cells was …

AdultNeutral redAntioxidantDPPHHealth Toxicology and Mutagenesismedicine.medical_treatment02 engineering and technologyMimusops elengiPharmacologyMimusopsArticleAntioxidantsfibroblast03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansMTT assayViability assaymedicinalbiologyPlant ExtractschlorhexidinePublic Health Environmental and Occupational HealthR030206 dentistryherbsFibroblasts021001 nanoscience & nanotechnologybiology.organism_classificationPhytochemicalchemistrygingivalMedicinecytotoxicityTrypan blue0210 nano-technologyInternational Journal of Environmental Research and Public Health
researchProduct

Vinorelbine and Cisplatin for the Treatment of Recurrent and/or Metastatic Carcinoma of the Uterine Cervix

2002

<i>Background:</i> To test the clinical activity and toxicity profile of the combination regimen of vinorelbine and cisplatin in a series of patients with carcinoma of the cervix uteri with de novo metastatic disease or recurrent disease after previous therapy. The main aims of the study included analysis of objective response rates, toxicity, and time to progression. <i>Patients and Methods:</i> Forty-two eligible patients were enrolled into the trial and treated with cisplatin 80 mg/m<sup>2</sup> on day 1 and vinorelbine 25 mg/m<sup>2</sup> on day 1 and 8. This regimen was repeated every 21 days upon resolution of toxicity for 3 cycles befor…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUterine Cervical NeoplasmsVinblastineVinorelbineMetastatic carcinomaRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCarcinomaHumansMedicineNeoplasm MetastasisCervixAgedCisplatinChemotherapyurogenital systembusiness.industryVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRegimenTreatment Outcomemedicine.anatomical_structureOncologyAdenocarcinomaFemaleCisplatinbusinessmedicine.drugOncology
researchProduct